TCRT · Categories · Form 4

TCRT - SEC Form 4 insider transactions

Alaunos Therapeutics Inc. (TCRT) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for TCRT

• 7d
  Chief Executive Officer Weis Holger was granted 3,700 shares, increasing direct ownership by 306% to 4,911 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 33d
  Director Vieser Jaime was granted 6,515 shares, increasing direct ownership by 20% to 38,853 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 33d
  Director Postma Robert W was granted 6,274 shares, increasing direct ownership by 14% to 50,146 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 33d
  Director Jerman Michael Allen was granted 6,032 shares, increasing direct ownership by 63% to 15,621 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 139d
  Director Vieser Jaime was granted 5,839 shares, increasing direct ownership by 22% to 32,338 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 139d
  Director Postma Robert W was granted 5,622 shares, increasing direct ownership by 15% to 43,872 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 139d
  Director Jerman Michael Allen was granted 5,406 shares, increasing direct ownership by 129% to 9,589 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 189d
  Director Vieser Jaime was granted 5,340 shares, increasing direct ownership by 25% to 26,499 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 189d
  Director Postma Robert W was granted 5,142 shares, increasing direct ownership by 16% to 38,250 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 189d
  Director Jerman Michael Allen was granted 4,183 shares (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 287d
  Vice President of Finance Groenewald Ferdinand was granted 10,775 shares (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 287d
  SEC Form 4 filed by Chief Executive Officer Weis Holger

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 321d
  SEC Form 4 filed by Director Jerman Michael Allen

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 331d
  Director Postma Robert W was granted 4,050 shares, increasing direct ownership by 14% to 33,133 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 331d
  Director Vieser Jaime was granted 3,400 shares, increasing direct ownership by 19% to 21,159 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 331d
  SEC Form 4 filed by Chief Executive Officer Weis Holger

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 342d
  SEC Form 4 filed by Director Vieser Jaime

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 342d
  Director Postma Robert W was granted 20,804 shares, increasing direct ownership by 251% to 29,083 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 414d
  Director Postma Robert W was granted 20,804 shares, increasing direct ownership by 251% to 29,083 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 414d
  SEC Form 4 filed by Director Weis Holger

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 414d
  Director Vieser Jaime was granted 17,465 shares, increasing direct ownership by 67% to 43,359 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 428d
  SEC Form 4 filed by Officer Hogue Dale Curtis Jr.

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 428d
  SEC Form 4 filed by Legal & Administration Lackey Melinda

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 428d
  SEC Form 4 filed by VP, Finance Groenewald Ferdinand

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 516d
  Director Vieser Jaime sold $6,022 worth of shares (3,000 units at $2.01), decreasing direct ownership by 10% to 25,894 units (SEC Form 4)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 656d
  SEC Form 4 filed by VP, Finance Groenewald Ferdinand

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 656d
  SEC Form 4 filed by Legal & Administration Lackey Melinda

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 723d
  SEC Form 4 filed by Director Weis Holger

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 723d
  SEC Form 4 filed by Director Vieser Jaime

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 723d
  SEC Form 4 filed by Director Postma Robert W

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 723d
  SEC Form 4 filed by Director Hofmeister Robert

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 862d
  SEC Form 4 filed by Hogue Dale Curtis Jr.

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 882d
  SEC Form 4 filed by Hogue Dale Curtis Jr.

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1002d
  SEC Form 4: Boyle Kevin S. Sr. sold $9,542 worth of shares (68,014 units at $0.14), decreasing direct ownership by 8% to 798,236 units

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1091d
  SEC Form 4 filed by Postma Robert W

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1091d
  SEC Form 4 filed by Hofmeister Robert

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1091d
  SEC Form 4 filed by Thistle Mary

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1091d
  SEC Form 4 filed by Huang James

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1091d
  SEC Form 4 filed by Vieser Jaime

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1091d
  SEC Form 4 filed by Weis Holger

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1141d
  SEC Form 4 filed by Hofmeister Robert

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1174d
  SEC Form 4 filed by Deniger Drew

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1174d
  SEC Form 4 filed by Srivastava Abhishek K

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1174d
  SEC Form 4 filed by Boyle Kevin S. Sr.

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1174d
  SEC Form 4 filed by Wong Michael

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1174d
  SEC Form 4 filed by Lackey Melinda

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1280d
  SEC Form 4: Postma Robert W bought $487,500 worth of shares (750,000 units at $0.65)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1280d
  SEC Form 4: Vieser Jaime bought $812,500 worth of shares (1,250,000 units at $0.65)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1353d
  SEC Form 4 filed by Deniger Drew

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1353d
  SEC Form 4 filed by Lackey Melinda

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1353d
  SEC Form 4 filed by Srivastava Abhishek K

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1353d
  SEC Form 4 filed by Wong Michael

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1371d
  SEC Form 4: Boyle Kevin S. Sr. covered exercise/tax liability with 18,750 shares, decreasing direct ownership by 2% to 866,250 units (tax withholding)

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1387d
  SEC Form 4 filed by Srivastava Abhishek K

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1440d
  SEC Form 4: Thistle Mary was granted 40,000 shares, increasing direct ownership by 800% to 45,000 units

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1440d
  SEC Form 4: Postma Robert W was granted 40,000 shares, increasing direct ownership by 3% to 1,241,870 units

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1440d
  SEC Form 4: Huang James was granted 80,000 shares, increasing direct ownership by 74% to 188,333 units

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1440d
  SEC Form 4: Postma Robert W was granted 40,000 shares, increasing direct ownership by 3% to 1,241,870 units

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1440d
  SEC Form 4: Thistle Mary was granted 40,000 shares, increasing direct ownership by 800% to 45,000 units

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
• 1440d
  SEC Form 4: Huang James was granted 80,000 shares, increasing direct ownership by 74% to 188,333 units

  4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

Other TCRT categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends